Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2561 to 2570 of 2581 total matches.

Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding

   
The Medical Letter on Drugs and Therapeutics • Oct 03, 2011  (Issue 1374)
Letter® On Drugs and Therapeutics Volume 53 (Issue 1374) October 3, 2011 www.medicalletter.org ...
Warfarin-related bleeding, especially intracranial hemorrhage, can be catastrophic. Several products are available to reverse warfarin’s anticoagulant effect.
Med Lett Drugs Ther. 2011 Oct 3;53(1374):78-9 |  Show IntroductionHide Introduction

COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
, and dosing recommendations. Available at: www.medicalletter.org/drugs-for-covid-19. Additional COVID-19 ...
The FDA has issued an Emergency Use Authorization (EUA) for an adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax. The vaccine is indicated for use as a two-dose primary series to prevent COVID-19 in adults; it is not authorized for use in children or as a booster dose. Three other COVID-19 vaccines are available in the US for primary immunization of adults; the mRNA vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are FDA-licensed for this indication, and the adenovirus-based vaccine manufactured by Johnson & Johnson (Janssen) is...
Med Lett Drugs Ther. 2022 Aug 8;64(1656):121-2 |  Show IntroductionHide Introduction

Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth. com/drug-pricing-policy. DOSAGE ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4   doi:10.58347/tml.2023.1677b |  Show IntroductionHide Introduction

Corneal Surgery for Myopia

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993  (Issue 907)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are now being used for this purpose.
Med Lett Drugs Ther. 1993 Oct 15;35(907):95-6 |  Show IntroductionHide Introduction

Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
catecholamine release from the tumor) or an insulinoma. DRUG INTERACTIONS – Patients taking the NSAID ...
The FDA has approved glucagon nasal powder (Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits (GlucaGen Hypokit, and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available...
Med Lett Drugs Ther. 2019 Sep 23;61(1581):148-9 |  Show IntroductionHide Introduction

Corticosteroids in Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Jan 13, 2020  (Issue 1589)
to a lower rate of late radiographic progression with methylprednisolone (2% vs 15%); the drug did ...
Recently updated guidelines from the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) address the use of corticosteroids as an adjunct to antimicrobials for treatment of community-acquired pneumonia (CAP).
Med Lett Drugs Ther. 2020 Jan 13;62(1589):7-8 |  Show IntroductionHide Introduction

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
that persons with a history of anaphylaxis to a vaccine, drug, or food not receive the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons ≥16 years old.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):1-2 |  Show IntroductionHide Introduction

COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023  (Issue 1689)
formulations for 2023-2024. Med Lett Drugs Ther 2023; 65:167. 3. F Dubovsky. Data in support of Novavax XBB ...
A new 2023-2024 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax that was developed to more closely target currently circulating SARS-CoV-2 variants has been made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old. The original formulation of the Novavax vaccine is no longer authorized for use in the US. In September, updated formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA for use in persons ≥12 years old and...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-3   doi:10.58347/tml.2023.1689b |  Show IntroductionHide Introduction

Corneal Surgery for Correction of Refractive Errors

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999  (Issue 1068)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....
Med Lett Drugs Ther. 1999 Dec 17;41(1068):122-3 |  Show IntroductionHide Introduction

Tattoo Removal

   
The Medical Letter on Drugs and Therapeutics • Nov 24, 2003  (Issue 1170)
95 The Medical Letter ® On Drugs and Therapeutics www.medicalletter.org Published ...
While more people than ever are getting tattoos, many come to regret their decision and would like to have them removed. The technology of removing tattoos is much better than it used to be, but still far from perfect. Complete removal of all pigments with restoration of normal skin color and texture is not always possible (M Kuperman-Beade et al, Am J Clin Dermatol 2001; 2:21; GM Lipper and RR Anderson in IM Freedberg et al, eds, Fitzpatrick's Dermatology in General Medicine 6th ed, New York:McGraw-Hill 2003, page 2508).
Med Lett Drugs Ther. 2003 Nov 24;45(1170):95-6 |  Show IntroductionHide Introduction